Tissue Factor and Tissue Factor Pathway Inhibitor as Key Regulators of Global Hemostasis: Measurement of Their Levels in Coagulation Assays

被引:43
作者
Kasthuri, Raj S. [1 ]
Glover, Sam L. [1 ]
Boles, Jeremiah [1 ]
Mackman, Nigel [1 ]
机构
[1] Univ N Carolina, Div Hematol & Oncol, Dept Med, Chapel Hill, NC 27599 USA
基金
美国国家卫生研究院;
关键词
Tissue factor; tissue factor pathway inhibitor; thrombosis; thromboelastography; FACTOR PROCOAGULANT ACTIVITY; VENOUS THROMBOEMBOLISM; ENDOTHELIAL-CELLS; HUMAN ENDOTOXEMIA; WHOLE-BLOOD; THROMBOSIS; CANCER; RISK; MICROPARTICLES; EXPRESSION;
D O I
10.1055/s-0030-1265293
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The tissue factor (TF)/factor (F)VIIa complex is the primary initiator of coagulation in vivo. Tissue factor pathway inhibitor (TFPI) is the physiological inhibitor of the TF/FVIIa complex. Deficiencies of either TF or TFPT have not been reported in humans, and a complete absence of either of these two proteins in mice is embryonically lethal. To maintain normal hemostasis, levels of TF and TFPI need to be balanced. Increased levels of TF can overwhelm the inhibitory capacity of TFPI, resulting in thrombosis. Decreased levels of TF are associated with bleeding. Global assays of coagulation are defined as tests capable of evaluating all components of the clotting cascade that are present in plasma. In these tests the thrombogenic surface is either provided by platelets or exogenous phospholipids. Clotting assays currently used in clinical practice are not designed to measure endogenous levels of TF and TFPI. Therefore, there is a need to develop sensitive and specific assays for measuring levels of functional TF and TFPI in whole blood and plasma. These assays could be useful in patient management in many scenarios.
引用
收藏
页码:764 / 771
页数:8
相关论文
共 32 条
  • [1] Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis
    Amini-Nekoo, A
    Futers, TS
    Moia, M
    Mannucci, PM
    Grant, PJ
    Ariëns, RAS
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) : 537 - 543
  • [2] Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia
    Aras, O
    Shet, A
    Bach, RR
    Hysjulien, JL
    Slungaard, A
    Hebbel, RP
    Escolar, G
    Jilma, B
    Key, NS
    [J]. BLOOD, 2004, 103 (12) : 4545 - 4553
  • [3] Ariëns RAS, 1999, THROMB HAEMOSTASIS, V81, P203
  • [4] Tissue factor encryption
    Bach, RR
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (03) : 456 - 461
  • [5] Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study
    Bladbjerg, EM
    Madsen, JS
    Kristensen, SR
    Abrahamsen, B
    Brixen, K
    Mosekilde, L
    Jespersen, J
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (06) : 1208 - 1214
  • [6] Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay
    Bogdanov, V. Y.
    Cimmino, G.
    Tardos, J. G.
    Tunstead, J. R.
    Badimon, J. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (05) : 894 - 897
  • [7] Alternatively spliced human tissue factor (asHTF) is not pro-coagulant
    Censarek, Petra
    Bobbe, Anett
    Grandoch, Maria
    Schroer, Karsten
    Weber, Artur-Aron
    [J]. THROMBOSIS AND HAEMOSTASIS, 2007, 97 (01) : 11 - 14
  • [8] Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis
    Dahm, A
    Vlieg, AV
    Bendz, B
    Rosendaal, F
    Bertina, RM
    Sandset, PM
    [J]. BLOOD, 2003, 101 (11) : 4387 - 4392
  • [9] Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke
    Duering, C
    Kosch, A
    Langer, C
    Thedieck, S
    Nowak-Göttl, U
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 92 (04) : 707 - 712
  • [10] New Antithrombotic Drugs
    Gross, P. L.
    Weitz, J. I.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (02) : 139 - 146